Multivariate analysis of parameters at TD and TT, including lymphodepletion and CAR T-cell infusion
| . | Relapse HR (95% CI) . | Early relapse HR (95% CI) . | Death HR (95% CI) . |
|---|---|---|---|
| Parameters at TD | |||
| Age ≥65 y | |||
| Lymphoma subtypes (DLBCL, PMBL, FL) | |||
| GC/non-GC | |||
| ECOG PS ≥2 | 2.95 (1.03-8.45); P = .044 | ||
| B symptoms | 1.85 (1.01-3.41); P = .0470 | ||
| Elevated LDH | 2.04 (1.19-3.49); P = .00933 | 9.61 (1.23-75.41); P = .031 | |
| Ann Arbor stage III/IV | |||
| EN sites ≥2 | 4.17 (1.99-8.72); P = .000148 | ||
| IPI high vs other | |||
| R-IPI poor vs other | |||
| Parameters at TT | |||
| Age >65 y | |||
| Males | |||
| ECOG PS | |||
| Ann Arbor stage III /IV | |||
| EN sites ≥2 | 2.50 (1.44-4.35); P = .00111 | 4.67 (1.55-14.11); P = .0063 | 3.61 (1.55-8.38); P = .00283 |
| IPI high vs other | |||
| R-IPI poor vs other | |||
| Progressive disease at infusion | |||
| High bridging therapy | |||
| Elevated LDH | |||
| CRP | 1.12 (1.07-1.17); P < .0001 | 1.15 (1.03-1.29); P = .016 | 1.12 (1.06-1.17); P < .0001 |
| Ferritin | |||
| Albumin | |||
| Lymphocytes | |||
| Bulky mass >5 cm | |||
| TMTV41% >80.42 mL | 2.18 (1.23-3.89); P = .00794 | 4.35 (1.32-14.37); P = .016 | 3.41 (1.41-8.26); P = .00651 |
| . | Relapse HR (95% CI) . | Early relapse HR (95% CI) . | Death HR (95% CI) . |
|---|---|---|---|
| Parameters at TD | |||
| Age ≥65 y | |||
| Lymphoma subtypes (DLBCL, PMBL, FL) | |||
| GC/non-GC | |||
| ECOG PS ≥2 | 2.95 (1.03-8.45); P = .044 | ||
| B symptoms | 1.85 (1.01-3.41); P = .0470 | ||
| Elevated LDH | 2.04 (1.19-3.49); P = .00933 | 9.61 (1.23-75.41); P = .031 | |
| Ann Arbor stage III/IV | |||
| EN sites ≥2 | 4.17 (1.99-8.72); P = .000148 | ||
| IPI high vs other | |||
| R-IPI poor vs other | |||
| Parameters at TT | |||
| Age >65 y | |||
| Males | |||
| ECOG PS | |||
| Ann Arbor stage III /IV | |||
| EN sites ≥2 | 2.50 (1.44-4.35); P = .00111 | 4.67 (1.55-14.11); P = .0063 | 3.61 (1.55-8.38); P = .00283 |
| IPI high vs other | |||
| R-IPI poor vs other | |||
| Progressive disease at infusion | |||
| High bridging therapy | |||
| Elevated LDH | |||
| CRP | 1.12 (1.07-1.17); P < .0001 | 1.15 (1.03-1.29); P = .016 | 1.12 (1.06-1.17); P < .0001 |
| Ferritin | |||
| Albumin | |||
| Lymphocytes | |||
| Bulky mass >5 cm | |||
| TMTV41% >80.42 mL | 2.18 (1.23-3.89); P = .00794 | 4.35 (1.32-14.37); P = .016 | 3.41 (1.41-8.26); P = .00651 |
HR, hazard ratio; OR, odds ratio.